Skip to main content

Omega-3 Fatty Acids can reduce the COPD Progression

COPD, which is most often caused by years of smoking, is characterized by inflammation and excessive mucus in the lungs that blocks airflow. Quitting can slow the progress of COPD, but it doesn’t halt the disease. Anti-inflammatory drugs are the most common treatment. however, they suppress the immune system, which can put people with COPD at risk for secondary infections.

The number of patients with COPD worldwide is increasing and there are no treatments to stop the disease from progressing. Current therapies, such as bronchodilators and steroids, can relieve symptoms but are not cures. Patients with COPD suffer greatly from symptoms of a cough, shortness of breath, infective exacerbations and even death. Thus, there is a great unmet need for new therapies.

Many studies have focused on the overall health benefits of omega-3 fatty acids, which are found in fish like salmon and tuna, but few have zeroed in on their role in lung disease. Sime, Phipps and others have shown that when consumed, omega-3’s are broken down into multiple pro-resolving lipid mediators, which turn off pro-inflammatory signals and promote the destruction of inflammatory cells that take over lung tissue following smoking.

Compounds derived from omega-3 fatty acids – like those found in salmon – might be the key to helping the body combat lung infections. One of the compounds, called pro-resolving lipid mediators, have anti-inflammatory effects on human lung cells and can stop cigarette smoke-induced lung damage in models of the disease. It can be used to prevent inflammation and speed the repair of lung injury from short and long-term cigarette smoke exposure, as well as other forms of lung injury.

These exciting new compounds have the potential to be one of the first-ever disease-modifying therapies against smoking-induced inflammatory lung disease, including chronic bronchitis and emphysema, the two conditions that characterize COPD.

Beyond patients with cigarette-induced COPD, a supplement could be used for the treatment of other inflammatory lung diseases, including biomass smoke-incited COPD. In the developing world, nearly 3 billion people cook food and heat their homes with traditional indoor cookstoves or open fires, which emit toxic smoke that also leads to COPD.

The goals of the new grant are to determine which pro-resolving lipid mediators are the most effective at dampening inflammation and the precise way in which they stamp it out in human lung cells and an experimental laboratory model of COPD.

Share your Knowledge and Know more about COPD, Asthma and other lung diseases by Attending



Be part of a unique gathering of Pulmonologists, Scientists and Respiratory medicine veterans from all over the globe at 2nd World Congress on COPD, Asthma and Lung Health during October 21-22, 2019 in Madrid, Spain
More Info: Click Here                                                                          Contact: copd@pulsusevents.org

Comments

Popular posts from this blog

Difference Between COPD, Asthma, Emphysema and Bronchitis

Chronic obstructive pulmonary disease (COPD) is a chronic disease composed of multiple components, which can include asthma, emphysema and/or chronic bronchitis. To reach a diagnosis of COPD you must have two or more of these diseases as diagnosed by your pulmonary (lung) doctor. All of these are considered to be obstructive respiratory diseases. Obstructive lung diseases are categorized as such because they impair the ability of your body to breathe oxygen into the lungs and expire carbon dioxide out of the lungs. Since COPD is a combination of two or more diseases, your symptoms tend to be more severe than if you suffered from only one of the diseases.
Various Stages of Chronic Obstructive Pulmonary Disease(COPD) STAGE 1 - Mild COPDSTAGE 2 - Moderate COPDSTAGE 3 - Severe COPDSTAGE 4 - Very Severe COPDSTAGE-1: Chronic Obstructive Pulmonary Disease (COPD) is a scourge in numerous parts of the world. Most patients with COPD exhibit gentle ailment. Mild COPD is the starting stage, the f…

Risk Factors and Prevention of Chronic Lung Diseases

When you think of chronic lung disease, you may think of lung cancer, but there are actually many different types. Altogether, lung diseases accounted for more than 3 million people die each year from COPD and 235 million people suffer from asthma, a common disease among children according to the World Health Organization.
These types of lung diseases may affect your airways, lung tissues, or circulation of blood in and out of your lungs. Here are the most common types, their causes and risk factors, and potential symptoms that may signal the need for medical attention.
Asthma Asthma is one of the most common types of chronic lung disease. When triggered, your lungs become swollen and narrow, making it harder to breathe. Symptoms include: WheezingBeing unable to take in enough airCoughingFeeling tightness in your chest If you experience these symptoms, it’s important to see a doctor right away. Triggers may include allergens, dust, pollution, stress, and exercise.
Asthma usually starts…

Alpha-1, the Genetic Component in COPD

What is Alpha 1?
You might not realize it, but your lungs and liver are connected in a very direct way. The liver manufactures a protein called Alpha-1Antitrypsin, which is then used by the body to repair environmental damage that accumulates in the lungs. Therefore, in people with a normal production and distribution of Alpha-1Antitrypsin throughout the body, when they breathe in an irritant that damages cells in the lungs, the body uses Alpha-1Antitrypsin to repair the damage. 
Symptoms of AAT deficiency include
Shortness of breath and wheezingRepeated lung infectionsTirednessRapid heartbeat upon standingVision problemsWeight lossIt’s a Genetic Thing: Alpha 1
Some people have a genetic mutation that prevents the Alpha-1Antitrypsin from exiting the liver where it’s made. Even though their livers are generating Alpha-1Antitrypsin, this protein gets stuck inside the liver and can’t travel to the lungs where it’s needed. This results in a condition called alpha-1 antitrypsin deficiency, …